Los Angeles Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Los Angeles Capital Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-8,846	Closed	-$602K	–	1316
2022 Q3	$602K	Buy	+8,846	New	+$488K	﹤0.01%	862
2021 Q1	–	Sell	-7,394	Closed	-$320K	–	1679
2020 Q4	$320K	Sell	7,394 -22,925	-76%	-$1.13M	﹤0.01%	1350
2020 Q3	$1.67M	Sell	30,319 -134,448	-82%	-$8.54M	0.01%	620
2020 Q2	$10.4M	Buy	164,767 +148,038	+885%	+$10.2M	0.05%	265
2020 Q1	$855K	Buy	16,729 +664	+4%	+$44.5K	0.01%	753
2019 Q4	$1.28M	Hold	16,065	–	–	0.01%	763
2019 Q3	$779K	Hold	16,065	–	–	﹤0.01%	872
2019 Q2	$845K	Sell	16,065 -8,990	-36%	-$517K	﹤0.01%	889
2019 Q1	$1.33M	Sell	25,055 -90	-0.4%	-$4.42K	0.01%	765
2018 Q4	$1.03M	Sell	25,145 -8,155	-24%	-$306K	0.01%	728
2018 Q3	$1.26M	Sell	33,300 -39,000	-54%	-$1.73M	0.01%	788
2018 Q2	$3.27M	Buy	72,300 +65,320	+936%	+$2.97M	0.02%	571
2018 Q1	$337K	Buy	+6,980	New	+$389K	﹤0.01%	1152

Other funds holding GBT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Los Angeles Capital Management's GBT Position: Q4 2022 in Review

Los Angeles Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 8,846 shares — an estimated $602K sold.

Los Angeles Capital Management first reported a position in GBT in Q1 2018 and held it in 13 quarters. The position peaked at $10.4M in Q2 2020. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

Los Angeles Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Los Angeles Capital Management sold 8,846 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $602K.
Los Angeles Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q1 2018 and held it in 13 quarters.
Los Angeles Capital Management's Global Blood Therapeutics, Inc. position peaked at $10.4M in Q2 2020.
2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Los Angeles Capital Management's 13F filing for Q4 2022, filed 6 Feb 2023.